Provided by Tiger Trade Technology Pte. Ltd.

Enanta Pharmaceuticals

13.47
+0.34002.59%
Volume:335.25K
Turnover:4.50M
Market Cap:390.88M
PE:-5.75
High:13.70
Open:13.27
Low:13.09
Close:13.13
52wk High:17.15
52wk Low:7.05
Shares:29.02M
Float Shares:22.51M
Volume Ratio:1.57
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3416
EPS(LYR):-3.8381
ROE:-70.12%
ROA:-12.28%
PB:3.87
PE(LYR):-3.51

Loading ...

Enanta Pharmaceuticals Inc - Expects Cash Runway to Fund Operations Into Fiscal 2029

THOMSON REUTERS
·
May 12

Enanta Pharmaceuticals Q2 Pretax Profit USD -13.084 Million

THOMSON REUTERS
·
May 12

Enanta Pharmaceuticals Inc - on Track to File Ind for EPS-3903 and Select Mrgprx2 Candidate in 2H 2026

THOMSON REUTERS
·
May 12

Enanta Pharmaceuticals Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
May 09

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 08

Enanta says Phase 2 trial shows zelicapavir reduces RSV symptom duration, hospitalization

Reuters
·
May 04

Enanta announces first participant dosed in Phase 1 trial of EDP-978

TIPRANKS
·
Apr 13

Enanta doses first participant in Phase 1 trial of urticaria drug EDP-978

Reuters
·
Apr 13

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of Edp-978, an Oral, Once-Daily Kit Inhibitor, in Development for the Treatment of Urticaria

THOMSON REUTERS
·
Apr 13

Enanta Pharmaceuticals Inc - Topline Data Expected in Q4 2026

THOMSON REUTERS
·
Apr 13

Enanta to present Phase 2b zelicapavir RSV trial data at ESCMID Global 2026

Reuters
·
Apr 07

Top Premarket Decliners

MT Newswires Live
·
Apr 06

Enanta to present preclinical data on oral STAT6 inhibitor EPS-3903 at IMMUNOLOGY2026

Reuters
·
Mar 30

Enanta Pharmaceuticals appeal oral argument set for May 11, 2026; litigation targets Pfizer over Paxlovid patent infringement

Reuters
·
Mar 26

Enanta initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
Mar 26

Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference

Reuters
·
Mar 03